arrow_back Civic Audit
Share share

Stopping Fake Petitions to Speed Up Generic Drug Approval

New rules aim to speed up access to cheaper generic and biosimilar drugs. The law will make it harder for pharmaceutical companies to file false petitions that delay the market entry of competitive, often cheaper alternatives. This means citizens may gain faster access to more affordable medications.
Key points
The Federal Trade Commission (FTC) gains tools to penalize companies filing baseless petitions intended to delay generic drug approval.
Companies filing such sham petitions can face significant fines, calculated based on revenues earned or a daily amount for each day of delay.
The goal is to increase competition in the pharmaceutical market, potentially leading to lower drug prices and wider availability for patients.
article Official text account_balance Process page notifications_active Track this Bill
Status: Placed on Calendar
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_S_1095
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2025-03-24
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Stop STALLING Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1095.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-03-24.

What are the main provisions?

Key points include:

  • The Federal Trade Commission (FTC) gains tools to penalize companies filing baseless petitions intended to delay generic drug approval.
  • Companies filing such sham petitions can face significant fines, calculated based on revenues earned or a daily amount for each day of delay.
  • The goal is to increase competition in the pharmaceutical market, potentially leading to lower drug prices and wider availability for patients.
What is the specific legal status?

The current status is Placed on Calendar.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Courts and Law Economy